文献速递神经肿瘤

EPH受体信号作为NF2缺陷型脑膜瘤的新型治疗靶点

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
PubMed 文献 · Neuro Oncol · 2018-01-01

研究在NF2缺失的人蛛网膜和脑膜瘤细胞系中进行高通量激酶组分析,发现EPH受体酪氨酸激酶、c-KIT和Src家族激酶活化,达沙替尼可抑制这些靶点且与mTORC1/2信号无交叉;在正交位脑膜瘤模型中,mTORC1/2抑制剂与达沙替尼联合对脑膜瘤生长抑制更强。

要点

  • NF2缺失脑膜瘤细胞中EPH受体酪氨酸激酶、c-KIT和Src家族激酶活化。
  • 达沙替尼抑制pEPHA2、pEPHB1、c-KIT和Src/SFK,与mTORC1/2信号无交叉。
  • mTORC1/2抑制剂联合达沙替尼对脑膜瘤生长抑制强于达沙替尼单药。

核心结论

  • 联合靶向mTORC1/2和EPH受体酪氨酸激酶/Src家族激酶通路可能是NF2缺陷型脑膜瘤的新型有效治疗策略。

研究设计与样本

  • 在NF2缺失的人蛛网膜和脑膜瘤细胞系中进行高通量激酶组分析,并以免疫印迹确认激酶活化及药物阻断效果。
  • 在细胞中筛选单药及联合用药的生长抑制活性,并在正交位脑膜瘤模型中测试抗肿瘤药物疗效。

主要发现

  • EPH受体酪氨酸激酶、c-KIT和Src家族激酶成员是NF2缺失细胞中活化靠前的候选靶点,且为达沙替尼的生物学靶点。
  • 达沙替尼显著抑制NF2缺失细胞中的pEPHA2、pEPHB1、c-KIT和Src/SFK,与mTORC1/2信号无交叉。
  • 治疗后激酶组分析显示适应性变化极小。
  • 达沙替尼单药显示一定活性,而mTORC1/2抑制剂及其与达沙替尼联合对脑膜瘤产生更强的生长抑制。

关键数值与推荐

  • 达沙替尼显著抑制pEPHA2、pEPHB1、c-KIT和Src/SFK。
  • mTORC1/2抑制剂联合达沙替尼对脑膜瘤的生长抑制强于达沙替尼单药。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Meningiomas are the most common primary brain tumor in adults, and somatic loss of the neurofibromatosis 2 (NF2) tumor suppressor gene is a frequent genetic event. There is no effective treatment for tumors that recur or continue to grow despite surgery and/or radiation. Therefore, targeted therapies that either delay tumor progression or cause tumor shrinkage are much needed. Our earlier work established mammalian target of rapamycin complex mTORC1/mTORC2 activation in NF2-deficient meningiomas. METHODS: High-throughput kinome analyses were performed in NF2-null human arachnoidal and meningioma cell lines to identify functional kinome changes upon NF2 loss. Immunoblotting confirmed the activation of kinases and demonstrated effectiveness of drugs to block the activation. Drugs, singly and in combination, were screened in cells for their growth inhibitory activity. Antitumor drug efficacy was tested in an orthotopic meningioma model. RESULTS: Erythropoietin-producing hepatocellular receptor tyrosine kinases (EPH RTKs), c-KIT, and Src family kinase (SFK) members, which are biological targets of dasatinib, were among the top candidates activated in NF2-null cells. Dasatinib significantly inhibited phospho-EPH receptor A2 (pEPHA2), pEPHB1, c-KIT, and Src/SFK in NF2-null cells, showing no cross-talk with mTORC1/2 signaling. Posttreatment kinome analyses showed minimal adaptive changes. While dasatinib treatment showed some activity, dual mTORC1/2 inhibitor and its combination with dasatinib elicited stronger growth inhibition in meningiomas. CONCLUSION: Co-targeting mTORC1/2 and EPH RTK/SFK pathways could be a novel effective treatment strategy for NF2-deficient meningiomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Angus SP, Oblinger JL, Stuhlmiller TJ, et al. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018. PMID: 29982664. doi:10.1093/neuonc/noy046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。